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Background: Patients treated with renal failure have been reported having high incidence of mortality and other complications rate after PCI. 
Optimal treatment of PCI for renal failure patients with dialysis is still unknown. Aim: The aim of this study is to compare the safety and efficacy of 
Sirolimus (SES), Paclitaxel (PES), Zotarolimus (ZES), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous coronary 
intervention in renal failure patients with dialysis (CRF-HD). 
Methods: A prospective analysis of 762 patients with CRF-HD (258 SES, 210 PES, 108 ZES, 88 BES, 98 EES) in six high volume Asian centers after 
successful stenting was performed. The study endpoints were major adverse cardiac events (MACE) at 30 days, 12 months and restenosis rate and 
target lesion revascularization (TLR) at 12 months. 
Results: The baseline clinical characteristics between 5 groups were similar. See table for clinical results. 
Conclusion: The use of drug-eluting stents in patient with CRF-HD was safe with low acute complication. Patients treated with PES showed lesser 
incidence of MACE at 12 months and lower rate of restenosis compared with other drug-eluting stents. 
SES PES ZES BES EES
Number of patients 258 210 108 88 98
Multivessel disease (%) 89.1 89.5 87.0 88.6 91.2
MACE at 30 days (%) 0.8 1.0 0.9 1.1 0
MACE at 12 months (%) 16.7 10.5* 21.2 21.5 19.4
Reference diameter (mean: mm) 2.80 2.78 2.82 2.84 2.90
Lesion type: % of B2, C (%) 64.0 66.7 53.7 70.4 69.4
Stent length (mean: mm) 28.8 29.4 26.3 29.3 25.8
Minimum lumen diameter post procedure (mean: mm) 2.65 2.60 2.58 2.59 2.60
Minimum lumen diameter at 12 months (mean: mm) 2.14 2.38* 2.08 2.05 2.22
Restenosis rate at 12 months (%) 17.4 9.5* 22.2 20.4 20.4
TLR at 12 months (%) 15.1 9.5* 20.3 20.4 19.4
*p<0.05 vs. others
